Brought to you by 
BioMarin acquires Zacharon for $10mm in cash, plus earn-outs
22 Sep 2020
Executive Summary
To help strengthen its development of drug candidates for lysosomal storage diseases (LSDs), BioMarin Pharmaceutical Inc. (rare disease therapies) is buying glycobiology specialist Zacharon Pharmaceuticals Inc. for $10mm in cash plus up to $134mm in earn-outs based on clinical, regulatory, and commercial achievements.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com